Mumbai: abbott announced the launch of XIENCE SIERRA everolimus (drug) eluting coronary stent in the system India, XIENCE Sierra is CE-marked and is one of the latest generation stents in the XIENCE family, now available for people suffering from blocked coronary arteries. For interventional cardiologists, this brings unparalleled security to the most complex cases.

drug-eluting The coronary stent system improves on previous versions of XIENCE with an advanced stent design, a new delivery system and unique shape to help doctors treat challenging cases. It has the same highly specialized coating that reduces the chance of re-blocking of the artery as found in other XIENCE stents. XIENCE stents have a safety record from over 120+ clinical trials collectively involving 120,000 patients. According to published data, the stent has proven efficacy in patients with difficult-to-treat, narrowing lesions and complex conditions.

“We launched XIENCE Sierra in India to help physicians more easily deliver stents even in challenging cases,” said Tushar Sharma, general manager of Abbott’s vascular business in India and South Asia. “The innovative design and improved delivery capability means physicians can reach and unblock difficult-to-treat lesions with greater flexibility and precision. With the incidence of coronary artery As this disease is on the rise in India, it is important for us to provide technologies that help doctors place the best stents, so that patients can get the best outcomes.”

XIENCE Sierra features include a more expansive range. This is helpful when the heart vessel is of different size at both ends. Importantly, the stent provides stability due to its high longitudinal strength, which reduces the risk of its deformation. It can be better scaled up and tracked so that physicians have more confidence in the outcomes and safety of their patients. It is a reliable stent because it allows physicians to more easily perform difficult techniques such as bypassing and crossing complex calcified lesions. One of the unique offerings of XIENCE Sierra is its ease of use which helps treat challenging anatomies in patients with complex conditions.

Cardiovascular diseases are the leading cause of death among non-communicable diseases in India. It is also known that Indians have a high prevalence of coronary artery disease (CAD), or blockage in the arteries, with the rate being 21.4 percent among diabetic patients and 11 percent among non-diabetics.

Tushar said, “In addition to offering the next generation of stents, Abbott is helping physicians by providing technologies that enable them to place stents most efficiently. We have launched AI-enabled imaging tools and diagnostics, which Provides everything an interventional cardiologist needs to perform complex tasks.” Coronary intervention.